Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 5/20 | 0.80 |
| ▸ | ATP6AP1 | Q15904 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229725 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6296395 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6296361 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL1229728 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL1229727 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400959 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400947 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400954 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6295642 | 0.86 | ATP6V1B1 (0.59) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6291994 | 0.86 | ATP6V1B1 (0.60) | ATP6V1B1ATP6AP1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | disclosed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | disclosed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240352406-A1 | BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF | CELLUM BIOMEDICAL, INC. | 2024-10-24 | — | — | US | disclosed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-118045230-A | Artificial periosteum | 奥索赛尔有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230262698-A1 | DEVICE AND METHOD FOR ALLOCATING RESOURCES IN WIRELESS COMMUNICATION SYSTEM | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-20220325236-A1 | BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF | CELLUM BIOMEDICAL, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220243177-A1 | METHODS OF CULTURING QUIESCENT HEMATOPOIETIC STEM CELLS AND TREATMENT METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-11345884-B2 | Biocompatible conditioned cell medium compositions and uses thereof | CELLUM BIOMEDICAL, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022086230-A1 | DEVICE AND METHOD FOR ALLOCATING RESOURCES IN WIRELESS COMMUNICATION SYSTEM | 삼성전자 주식회사 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | ATP6V1B1 4088/4885ATP6AP1 4754/4885HDAC4 642/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | ATP6V1B1 4302/4885ATP6AP1 4654/4885HDAC4 311/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | ATP6V1B1 2000/4885ATP6AP1 3883/4885HDAC4 705/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | ATP6V1B1 2024/4885ATP6AP1 3959/4885HDAC4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.